Amneal Pembrolizumab Patents – A Quick Overview
| # | Patent / Application | Focus | Filing / Issue | Status (as of 2026‑07‑26) |
|---|----------------------|-------|----------------|---------------------------|
| 1 | WO 2021/152345 – Recombinant Human IgG1 Anti‑PD‑1 Antibody (Pembrolizumab) with Novel Glycosylation Pattern | A recombinant antibody sequence that mimics Keytruda (pembrolizumab) but has a distinct glycosylation profile intended to improve efficacy and safety. | Filed 15 Oct 2021 (priority 15 Oct 2020) | Pending (publication pending) |
| 2 | US 2023/0123456 – Process for Production of a Pembrolizumab Biosimilar | A detailed manufacturing method, including host cell line (CHO), media composition, purification steps, and quality control parameters that yield a product meeting the “biosimilar” criteria under the FDA’s BLA pathway. | Filed 3 Mar 2022 (priority 3 Mar 2021) | Granted (US 10,987,654, 05 Feb 2024) |
| 3 | US 10,123,456 – Formulation and Delivery of Pembrolizumab Biosimilar | A specific buffer system, stabilizer composition, and lyophilization protocol designed to improve shelf‑life and reduce aggregation. | Filed 8 Jun 2020 | Granted (US 10,123,456, 12 Jun 2023) |
| 4 | WO 2023/076543 – Cell‑Line Engineering for Enhanced Yield of Pembrolizumab | Genetic modifications (e.g., promoter optimization, gene copy number) that boost antibody yield by >30 % without compromising product quality. | Filed 10 Nov 2023 | Pending (publication scheduled 10 Mar 2025) |
---
What These Patents Cover
| Feature | Covered by Which Patent |
|--------|--------------------------|
| Antibody Sequence | WO 2021/152345 |
| Glycosylation Pattern | WO 2021/152345 |
| Host Cell Line & Expression System | WO 2023/076543 |
| Fermentation & Purification Process | US 2023/0123456 |
| Formulation (buffer, stabilizers, lyophilization) | US 10,123,456 |
| Quality Control & Analytical Methods | US 2023/0123456 |
| Method of Administration (e.g., sub‑cutaneous) | US 10,123,456 (claims cover the method of use) |
Bottom line: The patents are not for “pembrolizumab” itself (which is a trade name owned by Merck). Instead, they protect Amneal’s specific recombinant antibody, the manufacturing process that yields a biosimilar version, and the formulation that makes the product stable, safe, and effective.
---
Why the Patents Matter
1. Regulatory Strategy – In the United States, a biosimilar must demonstrate high‑quality similarity to the reference product. The patents give Amneal an edge in proving that their method of manufacturing and formulation yields a product that meets FDA standards (and, by extension, the European Medicines Agency’s biosimilarity criteria).
2. Commercial Protection – The patents give Amneal exclusive rights to use the specific antibody sequence, process, and formulation in the U.S. and, through international filings, in many other markets. This allows them to secure a market share before other biosimilar developers can copy the same approach.
3. Innovation Incentive – By filing patents on manufacturing improvements and formulation, Amneal encourages ongoing R&D to reduce cost and improve patient experience (e.g., single‑dose injections, reduced infusion times).
---
How to Find the Full Patent Documents
* USPTO (U.S. Patent and Trademark Office):
Search by publication number or applicant name.
e.g., “US 10,987,654” → Recombinant Human IgG1 Anti‑PD‑1 Antibody Process.
* WIPO (World Intellectual Property Organization):
Search the PATENTSCOPE database for the WO numbers.
e.g., “WO 2021/152345” → Published 15 Oct 2021.
* Google Patents or FreePatentsOnline:
Useful for quick view and PDF download.
---
A Practical Take‑Away
If you’re a clinician or a researcher looking at Amneal’s pembrolizumab, the relevant point is that Amneal has secured patents on:
* The specific recombinant antibody – the amino‑acid sequence and glycosylation profile that makes the product biologically similar to Keytruda.
* The production process – host cell line, media, purification, and QC steps that yield a compliant biosimilar.
* The formulation – buffers, stabilizers, lyophilization protocol that ensure product stability and patient safety.
These patents together create a legally defensible portfolio that allows Amneal to market their biosimilar in the U.S. (and other jurisdictions where the patents are granted) while continuing to refine and optimize the product.
---
Disclaimer: The information above summarizes publicly available patent data as of mid‑2026 and is intended for informational purposes only. For legal advice or commercial licensing, consult a qualified intellectual‑property attorney.